Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse

References

• Patel JP, Gonen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012;366:1079–1089.
   PubMed Web of Science ®Google Scholar
• Schlenk RF, Dohner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008;358:1909–1918.
   PubMed Web of Science ®Google Scholar
• Grossmann V, Schnittger S, Kohlmann A, et al. A novel hierarchical prognostic model of AML solely based on molecular mutations. Blood 2012;120:2963–2972.
   PubMed Web of Science ®Google Scholar
• Estey EH. Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 2012;87:89–99.
   PubMed Web of Science ®Google Scholar
• Takahashi S. Current findings for recurring mutations in acute myeloid leukemia. J Hematol Oncol 2011;4:36.
   PubMed Web of Science ®Google Scholar
• Gianfelici V, Lahortiga I, Cools J. Chromosomal aberrations and fusion genes in myeloid malignancies. Expert Rev Hematol 2012;5:381–393.
   PubMed Web of Science ®Google Scholar
• Wakita S, Yamaguchi H, Omori I, et al. Mutations of the epigenetics modifying gene (DNMT3a, TET2, IDH1/2) at diagnosis may induce FLT3-ITD at relapse in de novo acute myeloid leukemia. Leukemia 2012.
   PubMed Web of Science ®Google Scholar
• Kronke J, Schlenk RF, Jensen KO, et al. Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group. J Clin Oncol 2011;29:2709–2716.
   PubMed Web of Science ®Google Scholar
• Falini B, Mecucci C, Tiacci E, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005;352:254–266.
   PubMed Web of Science ®Google Scholar
• Schnittger S, Schoch C, Kern W, et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 2005;106:3733–3739.
   PubMed Web of Science ®Google Scholar
• Thiede C, Koch S, Creutzig E, et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood 2006;107:4011–4020.
   PubMed Web of Science ®Google Scholar
• Dohner K, Schlenk RF, Habdank M, et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood 2005;106:3740–3746.
   PubMed Web of Science ®Google Scholar
• Verhaak RG, Goudswaard CS, van Putten W, et al. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood 2005;106:3747–3754.
   PubMed Web of Science ®Google Scholar
• Shamaa S, Laimon N, Aladle DA, et al. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia. Hematology 2013.
   PubMed Web of Science ®Google Scholar
• Pratcorona M, Brunet S, Nomdedeu J, et al. Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy. Blood 2013;121:2734–2738.
   PubMed Web of Science ®Google Scholar
• Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114:937–951.
   PubMed Web of Science ®Google Scholar
• Falini B, Sportoletti P, Martelli MP. Acute myeloid leukemia with mutated NPM1: diagnosis, prognosis and therapeutic perspectives. Curr Opin Oncol 2009;21:573–581.
   PubMed Web of Science ®Google Scholar
• Falini B, Martelli MP, Bolli N, et al. Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity?. Blood 2011;117:1109–1120.
   PubMed Web of Science ®Google Scholar
• Papadaki C, Dufour A, Seibl M, et al. Monitoring minimal residual disease in acute myeloid leukaemia with NPM1 mutations by quantitative PCR: clonal evolution is a limiting factor. Br J Haematol 2009;144:517–523.
   PubMed Web of Science ®Google Scholar
• Suzuki T, Kiyoi H, Ozeki K, et al. Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. Blood 2005;106:2854–2861.
   PubMed Web of Science ®Google Scholar
• Kuzmanovic M, Tosic N, Colovic N, et al. Prognostic Impact of NPM1 Mutations in Serbian Adult Patients with Acute Myeloid Leukemia. Acta Haematol 2012;128:203–212.
   PubMed Web of Science ®Google Scholar
• Boissel N, Renneville A, Biggio V, et al. Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype. Blood 2005;106:3618–3620.
   PubMed Web of Science ®Google Scholar
• Colombo E, Alcalay M, Pelicci PG. Nucleophosmin and its complex network: a possible therapeutic target in hematological diseases. Oncogene 2011;30:2595–2609.
   PubMed Web of Science ®Google Scholar
• Borer RA, Lehner CF, Eppenberger HM, Nigg EA. Major nucleolar proteins shuttle between nucleus and cytoplasm. Cell 1989;56:379–390.
   PubMed Web of Science ®Google Scholar
• Federici L, Falini B. Nucleophosmin mutations in acute myeloid leukemia: A tale of protein unfolding and mislocalization. Protein Sci 2013.
   PubMed Web of Science ®Google Scholar
• Colombo E, Marine JC, Danovi D, Falini B, Pelicci PG. Nucleophosmin regulates the stability and transcriptional activity of p53. Nat Cell Biol 2002;4:529–533.
   PubMed Web of Science ®Google Scholar
• Bertwistle D, Sugimoto M, Sherr CJ. Physical and functional interactions of the Arf tumor suppressor protein with nucleophosmin/B23. Mol Cell Biol. 2004;24:985–996.
   PubMed Web of Science ®Google Scholar
• Konoplev S, Huang X, Drabkin HA, et al. Cytoplasmic localization of nucleophosmin in bone marrow blasts of acute myeloid leukemia patients is not completely concordant with NPM1 mutation and is not predictive of prognosis. Cancer 2009;115:4737–4744.
   PubMed Web of Science ®Google Scholar
• Greiner J, Ono Y, Hofmann S, et al. Mutated regions of nucleophosmin 1 elicit both CD4(+) and CD8(+) T-cell responses in patients with acute myeloid leukemia. Blood 2012;120:1282–1289.
   PubMed Web of Science ®Google Scholar
• Grimwade L, Gudgin E, Bloxham D, et al. Detection of cytoplasmic nucleophosmin expression by imaging flow cytometry. Cytometry A 2012;81:896–900.
   PubMed Web of Science ®Google Scholar
• Thol F, Kolking B, Damm F, et al. Next-generation sequencing for minimal residual disease monitoring in acute myeloid leukemia patients with FLT3-ITD or NPM1 mutations. Genes Chromosomes Cancer 2012;51:689–695.
   PubMed Web of Science ®Google Scholar
• Schnittger S, Kern W, Tschulik C, et al. Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML. Blood 2009;114:2220–2231.
   PubMed Web of Science ®Google Scholar
• Ommen HB, Schnittger S, Jovanovic JV, et al. Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias. Blood 2010;115:198–205.
   PubMed Web of Science ®Google Scholar
• Kristensen T, Moller MB, Friis L, Bergmann OJ, Preiss B. NPM1 mutation is a stable marker for minimal residual disease monitoring in acute myeloid leukaemia patients with increased sensitivity compared to WT1 expression. Eur J Haematol 2011;87:400–408.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003;21:4642–4649.
   PubMed Web of Science ®Google Scholar
• Ravandi F, Jorgensen JL. Monitoring minimal residual disease in acute myeloid leukemia: ready for prime time?. J Natl Compr Canc Netw 2012;10:1029–1036.
   PubMed Web of Science ®Google Scholar
• Buccisano F, Maurillo L, Del Principe MI, et al. Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. Blood 2012;119:332–341.
   PubMed Web of Science ®Google Scholar
• Palmisano M, Grafone T, Ottaviani E, Testoni N, Baccarani M, Martinelli G. NPM1 mutations are more stable than FLT3 mutations during the course of disease in patients with acute myeloid leukemia. Haematologica 2007;92:1268–1269.
   PubMed Web of Science ®Google Scholar
• Bacher U, Haferlach C, Kern W, Haferlach T, Schnittger S. Prognostic relevance of FLT3-TKD mutations in AML: the combination matters—an analysis of 3082 patients. Blood 2008;111:2527–2537.
   PubMed Web of Science ®Google Scholar
• Boonthimat C, Thongnoppakhun W, Auewarakul CU. Nucleophosmin mutation in Southeast Asian acute myeloid leukemia: eight novel variants, FLT3 coexistence and prognostic impact of NPM1/ FLT3 mutations. Haematologica 2008;93:1565–1569.
   PubMed Web of Science ®Google Scholar
• Chou WC, Tang JL, Lin LI, et al. Nucleophosmin mutations in de novo acute myeloid leukemia: the age-dependent incidences and the stability during disease evolution. Cancer Res 2006;66:3310–3316.
   PubMed Web of Science ®Google Scholar
• Schneider F, Hoster E, Schneider S, et al. Age-dependent frequencies of NPM1 mutations and FLT3-ITD in patients with normal karyotype AML (NK-AML). Ann Hematol 2012;91:9–18.
   PubMed Web of Science ®Google Scholar
• Becker H, Marcucci G, Maharry K, et al. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study. J Clin Oncol 2010;28:596–604.
   PubMed Web of Science ®Google Scholar